YMAB has been successfully added to your Stock Email Alerts list.
You can manage your stock email alerts here.
YMAB has been removed from your Stock Email Alerts list.
Please enter Portfolio Name for new portfolio.
Y-mAbs Therapeutics has the GF Value Rank of 10.
The GF Value Rank is determined by the price-to-GF-Value (P/GF Value) ratio, a proprietary metric calculated based on historical multiples along with an adjustment factor based on a company's past returns and growth and future estimates of the business' performance.
GuruFocus found that for valuation, we cannot simply give stocks a better GF Value rank simply because they have a lower P/GF Value ratio. Backtesting shows that over the long term, the two worst-performing groups are the most expensive group (with the highest P/GF Value ratio) and the least expensive group (with the lowest P/GF Value ratio).
We can understand why the most expensive group underperforms. We were initially puzzled by the underperformance of the least expensive group, but we realized there is a reason why some stocks are super cheap. If they look too undervalued, it is often because the businesses behind them are poor quality. The market realized this and gave them low valuations. In a way, the market is efficient.
After multiple backtesting analyses, we granted the stocks in third-cheapest percentile the highest GF Value rank, as they have performed the best over a full market cycle. Stock performance is actually not as sensitive to valuation as it is to growth and profitability. On average, the companies in the 20%-50% valuation groups have similar performances. Therefore, we should avoid the most expensive and the least expensive stocks. We can be more tolerant of valuation.
Please click GF Score to see more details on the GF Score's 5 Key Aspects of Analysis.
For the Biotechnology subindustry, Y-mAbs Therapeutics's GF Value Rank, along with its competitors' market caps and GF Value Rank data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
For the Biotechnology industry and Healthcare sector, Y-mAbs Therapeutics's GF Value Rank distribution charts can be found below:
* The bar in red indicates where Y-mAbs Therapeutics's GF Value Rank falls into.
Thank you for viewing the detailed overview of Y-mAbs Therapeutics's GF Value Rank provided by GuruFocus.com. Please click on the following links to see related term pages.
Thomas Gad | director, officer: President and Chairman | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Biotech Aps Wg | 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Johan Wedell-wedellsborg | director, 10 percent owner | RUNGSTED STRANDVEJ 113, RUNGSTED KYST G7 2960 |
Michael J Rossi | director, officer: President & CEO | 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Vignesh Rajah | officer: SVP and CMO | HENRIKSHOJ 8, ROOM 4, VEDBAEK G7 DK-2950 |
Bo Kruse | director, officer: EVP, CFO, Secy & Treas. | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
Susan Laura Smith | officer: Senior Vice President, CCO | 5 OVERLOOK CT, LAMBERTVILLE NJ 08530 |
David N Gill | director | C/O NXSTAGE MEDICAL INC. (NXTM), 439 SOUTH UNION STREET, 5TH FLOOR, LAWRENCE MA 01843 |
Juan Moller San Pedro Claus | director, officer: Chief Executive Officer | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3500, NEW YORK NY 10169 |
Laura Hamill | director | 333 LAKESIDE DRIVE, FOSTER CITY CA 94404 |
Mahiuddin Ahmed | officer: Sr. VP and CSO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
Philip Karl Herman | officer: Sr. VP and CCO | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, SUITE 3350, NEW YORK NY 10169 |
James Healy | director | 3000 SAND HILL ROAD, 4-250, MENLO PARK CA 94025 |
Gregory S Raskin | director | C/O MEMORIAL SLOAN KETTERING CANCER CENT, 1275 YORK AVENUE, BOX 524, NEW YORK NY 10065 |
Gerard Ber | director | C/O Y-MABS THERAPEUTICS, INC., 230 PARK AVENUE, 33RD FLOOR, NEW YORK NY 10169 |
From GuruFocus
By Marketwired • 10-18-2023
By sperokesalga sperokesalga • 03-21-2023
By Marketwired • 09-21-2023
By sperokesalga sperokesalga • 05-08-2023
By PRNewswire • 09-21-2023
By sperokesalga sperokesalga • 04-28-2023
By sperokesalga sperokesalga • 03-17-2023
By Marketwired • 10-16-2023
By sperokesalga sperokesalga • 03-20-2023
By GuruFocus Research • 11-13-2023
Disclaimers: GuruFocus.com is not operated by a broker or a dealer. It has an affiliated registered investment adviser, which serves as the subadviser to an exchange traded fund. This investment adviser does not provide advice to individual investors. Under no circumstances does any information posted on GuruFocus.com represent a recommendation to buy or sell a security. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The individuals or entities selected as "gurus" may buy and sell securities before and after any particular article and report and information herein is published, with respect to the securities discussed in any article and report posted herein. Gurus may be added or dropped from the GuruFocus site at any time. In no event shall GuruFocus.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content or other material published or available on GuruFocus.com, or relating to the use of, or inability to use, GuruFocus.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance. The information on this site, and in its related newsletters, is not intended to be, nor does it constitute investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. The gurus listed in this website are not affiliated with GuruFocus.com, LLC. Stock quotes provided by InterActive Data. Fundamental company data provided by Morningstar, updated daily.